Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Azacitidine and Homoharringtonine in JMML
NCT04505995Unknown
- Sponsor
- Air Force Medical University
- Start
- Jan 2020
- Primary completion
- Jan 2023
- Modality
- Nucleic Acid-Directed Small Molecules, Covalent Small Molecules, Classical Binding Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of azacitidine and homoharringtonine in juvenile myelomonocytic leukemia (JMML), sponsored by Air Force Medical University. Primary endpoint: JMML response rate at 4 months. Status: unknown.
02
Drugs
azacitidinehomoharringtonine
03
Conditions
juvenile myelomonocytic leukemia (JMML)
Beyond the preview
Go deeper on NCT04505995.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04505995.